Related Experiment Video
Updated: Aug 25, 2026

A Bilingual Computational Workflow for Identifying Potential PLK1 Inhibitors in American Sign Language and English
Published on: April 3, 2026
Polo-like kinase 1 (PLK1) expression is associated with cell proliferative activity and cdc2 expression in malignant
Yasuhiro Ito1, Hiroshi Yoshida, Fumio Matsuzuka
1Department of Surgery, Kuma Hospital, 8-2-35, Shimoyamate-dori, Chuo-ku, Kobe 650-0011, Japan. ito01@kuma-h.or.jp
Background:
Polo-like kinase 1 (PLK1) is one of the serine threonine kinases that plays a role in cellular proliferation by activating the CDC25C-CDK1 (cdc2) loop. We recently demonstrated that cdc2 expression is associated with the biological aggressiveness of malignant lymphoma of the thyroid. In this study, we investigated PLK1 expression in thyroid lymphoma in order to elucidate its physiological significance in this disease.
Materials And Methods:
We immunohistochemically investigated PLK1 expression in 46 cases of thyroid lymphoma and 10 cases of chronic thyroiditis.
Results:
Normal follicular cells did not express PLK1, whereas follicular cells in those in chronic thyroiditis and malignant lymphoma demonstrated a high level of PLK1 expression. In lymphocytes in chronic thyroiditis with strong lymphocyte infiltration, PLK1 was weakly expressed. In malignant lymphoma, PLK1 expression was observed in all cases, but PLK1 was more strongly expressed in cases with high cell proliferative activity and with cdc2 expression.
Conclusion:
These results suggest that PLK1 regulates the cell cycle progression of thyroid lymphoma cells in the G2-M-phase.
Related Concept Videos
Abnormal Proliferation
M-Cdk Drives Transition Into Mitosis
Cyclin-dependent kinases, or Cdks, work in concert with cyclins to control cell cycle transitions. M-Cdk, a complex of Cdk1 bound to M cyclin, is a well-known example of this coordinated control that drives the transition from the G2 to the M phase.
M cyclin...
Inhibition of Cdk Activity
Positive Regulator Molecules
mTOR Signaling and Cancer Progression
The mTOR pathway or the...
PI3K/mTOR/AKT Signaling Pathway
